• 1
    Albers JM, Kuper HH, van Riel PL, Prevoo ML, van 't Hof MA, van Gestel AM, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 1999; 38: 42330.
  • 2
    Barrett EM, Scott DG, Wiles NJ, Symmons DP. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatology (Oxford) 2000; 39: 14039.
  • 3
    Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006; 54: 71622.
  • 4
    Ramey DR, Raynauld JP, Fries JF. The Health Assessment Questionnaire 1992: status and review. Arthritis Care Res 1992; 5: 11929.
  • 5
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definitions of improvement in rheumatoid arthritis. Arthritis Rheum 1996; 38: 72735.
  • 6
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 7
    Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the Disease Activity Score. Br J Rheumatol 1996; 35: 11015.
  • 8
    Van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998; 41: 184550.
  • 9
    Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1: 10368.
  • 10
    Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al, for the FIN-RACo Trial Group. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum 2005; 52: 3641.
  • 11
    Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004; 63: 2215.
  • 12
    Aletaha D, Smolen JS, Ward MM. Functional limitation in rheumatoid arthritis (RA): how much is reversible? [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S3278.
  • 13
    Kavanaugh A, Han C, Bala M. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol 2004; 31: 84955.
  • 14
    Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003; 21(5 Suppl 31 ): S1547.
  • 15
    Quinn MA, Emery P. Potential for altering rheumatoid arthritis outcome. Rheum Dis Clin North Am 2005; 31: 76372.
  • 16
    Melin R, Fugl-Meyer AR. On prediction of vocational rehabilitation outcome at a Swedish employability institute. J Rehabil Med 2003; 35: 2849.
  • 17
    Ganguly R, Miller LS, Martin BC. Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophr Res 2003; 63: 1119.